Status:
COMPLETED
An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Hypertension
Eligibility:
All Genders
18-80 years
Brief Summary
An observational study to investigate the efficacy, safety, tolerability and the effect on quality of life of Telmisartan (Micardis) and Telmisartan with HCTZ (Micardis Plus) in patients with hyperten...
Eligibility Criteria
Inclusion
- Ability to provide written/verbal informed consent in accordance with GCP (Good Clinical Practice) and local legislation
- Patients aged 18 \~ under 80
- Hypertension as described below:
- Newly diagnosed patients with hypertension
- Patients with current antihypertensive therapy
Exclusion
- Female subjects who are breastfeeding, pregnant or who plan to be pregnant during the study
- Known or suspected secondary hypertension(e.g. pheochromocytoma)
- Patients who have been treated with telmisartan prior to the acquisition of informed consent (including verbal informed consent)
Key Trial Info
Start Date :
February 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
1095 Patients enrolled
Trial Details
Trial ID
NCT00904215
Start Date
February 1 2005
Last Update
April 21 2014
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer ingelheim Investigational Site 1
Daegu, South Korea
2
Boehringer ingelheim Investigational Site 4
Daegu, South Korea
3
Boehringer ingelheim Investigational Site 7
Daegu, South Korea
4
Boehringer ingelheim Investigational Site 9
Daejeon, South Korea